Exagen (Exagen) Equivalent Admissions # : 0.00 (As of Sep. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Exagen Equivalent Admissions #?

Equivalent Admissions # are a general measure used to indicate combined inpatient and outpatient volumes.

The historical rank and industry rank for Exagen's Equivalent Admissions # or its related term are showing as below:

XGN's Equivalent Admissions # is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median:
* Ranked among companies with meaningful Equivalent Admissions # only.

Exagen Equivalent Admissions # Historical Data

The historical data trend for Exagen's Equivalent Admissions # can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exagen Equivalent Admissions # Chart

Exagen Annual Data

Trend

Dec22

Dec23

Equivalent Admissions #

Get a 7-Day Free Trial

ExagenQuarterly Data

Trend

Mar23

Jun23

Sep23

Equivalent Admissions #

Get a 7-Day Free Trial

Competitive Comparison of Exagen's Equivalent Admissions #

For the Diagnostics & Research subindustry, Exagen's Equivalent Admissions #, along with its competitors' market caps and Equivalent Admissions # data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Exagen (Exagen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exagen Inc (NAS:XGN) » Definitions » Equivalent Admissions #

Comparable Companies

Traded in Other Exchanges

E08A:Germany

Address

1261 Liberty Way, Vista, CA, USA, 92081

Website

https://www.exagen.com

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Executives

John Aballi	director, officer: President and CEO	C/O DECIPHER BIOSCIENCES, INC., 6925 LUSK BLVD, SUITE 200, SAN DIEGO CA 92121
Paul Kim	director	4399 SANTA ANITA AVE, EL MONTE CA 91731
Tullis Growth Fund Ii, L.p.	10 percent owner	11770 US HWY 1, STE 503, PALM BEACH GARDENS FL 33408
Kamal Adawi	officer: Chief Financial Officer	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92131
Mark Hazeltine	officer: Chief Operating Officer	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Wendy S. Johnson	director	800 E. LEIGH STREET, SUITE 209, RICHMOND VA 21219
Tullis James L L	director, 10 percent owner	100 FIRST STAMFORD PLACE, STAMFORD CT 06907
Ana Hooker	director	441 CHARMANY DRIVE, MADISON WI 53719
Frank Stokes	director	C/O CASTLE BIOSCIENCES, 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Hunt Holdings Limited Partnership	10 percent owner	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Nmsic Co-investment Fund, L.p.	10 percent owner	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Debra Zack	officer: Chief Medical Officer	C/O EXAGEN, INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
H.i.g. Bio-exagen, L.p.	10 percent owner	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Thierry Dervieux	officer: Chief Scientific Officer	C/O EXAGEN DIAGNOSTICS, INC., 1261 LIBERTY WAY, VISTA CA 92081
Nmsic Focused Llc	10 percent owner	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081